Suspended

Oxygenation of the Cerebrum and Cooling During Transcatheter Aortic Valve Implantation (TAVI) Procedures - Part II

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

targeted brain cooling (33°C) by RhinoChill device

+ Placebo - current clinical practice, no cooling

Device
Who is being recruted

Aortic Valve Disease+9

+ Brain Diseases

+ Cardiovascular Diseases

+4 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Placebo-Controlled
Interventional
Study Start: March 2013
See protocol details

Summary

Principal SponsorHasselt University
Study ContactCathy S De Deyne, MD, PhDMore contacts
Last updated: April 4, 2013
Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 2013

Actual date on which the first participant was enrolled.

The aim of this study is to assess the possible neuroprotective effects of cooling (targeted cooling of the brain to 33°C) during Transcatheter Aortic Valve Implantation (TAVI) procedures. From start of anesthesia, until final valve implantation, local cooling (by the RhinoChill device) will be applied to the brain. Effect of cooling on cerebral oxygenation, by cerebral oxygen saturation monitoring (NIRS ForeSight technology) during the TAVI procedure will be continuously assessed during native valve manipulation and during final valve deployment (=primary endpoint of he study). As secondary endpoints, neuropsychological testing performed before and after TAVI procedure will assess the effects of the use of cooling during the TAVI procedure. Neuron-specific enolase (NSE) and S100-beta will be analyzed during and up to 72hrs after TAVI to compare the cerebral ischemic damage between cooled and non-cooled patients. And finally, diffusion-weighted MRI of the brain will be performed 5 days before and 5-7 days after TAVI to compare the number and total amount of cerebral ischemic insults between cooled and non-cooled patients. The hypothesis behind this study is that by local cooling of the brain during manipulation of the calcified aorta and aortic valve, the brain might be protected from cerebral ischemic insults.

NCT01822964
Principal SponsorHasselt University
Study ContactCathy S De Deyne, MD, PhDMore contacts
Last updated: April 4, 2013
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

30 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Aortic Valve DiseaseBrain DiseasesCardiovascular DiseasesCentral Nervous System DiseasesCerebrovascular DisordersHeart DiseasesHeart Valve DiseasesNervous System DiseasesVascular DiseasesVentricular Outflow ObstructionAortic Valve StenosisStroke

Criteria

1 inclusion criteria required to participate
pts scheduled for transcatheter aortic valve implantation

3 exclusion criteria prevent from participating
pts with extreme claustrophobia for MRI brain examination

pts with pacemaker already implanted

pts with recent stroke or Transient Ischemic Attacks (TIA) (6months)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator
In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)

Group II

Placebo
In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Recruiting

Ziekenhuis Oost-Limburg

Genk, BelgiumOpen Ziekenhuis Oost-Limburg in Google Maps
Recruiting soon

Universitair Ziekenhuis

Leuven, Belgium
Suspended2 Study Centers